Skip to main content
. 2024 Feb 22;10(1):e003855. doi: 10.1136/rmdopen-2023-003855

Figure 3.

Figure 3

PASI responders to week 52. Randomised set, in patients with psoriasis affecting ≥3% BSA at baseline. For binary variables, p values were calculated using a logistic regression model with treatment, prior TNFi exposure and region as stratification factors. BKZ, bimekizumab; BSA, body surface area; NRI, non-responder imputation; OC, observed case; PASI, Psoriasis Area and Severity Index; Q4W, every 4 weeks; TNFi, tumour necrosis factor inhibitor.